PROK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PROK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
ProKidney's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.80 Mil. ProKidney's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.61 Mil. ProKidney's annualized EBITDA for the quarter that ended in Dec. 2023 was $-71.14 Mil. ProKidney's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for ProKidney's Debt-to-EBITDA or its related term are showing as below:
During the past 4 years, the highest Debt-to-EBITDA Ratio of ProKidney was -0.02. The lowest was -0.06. And the median was -0.03.
The historical data trend for ProKidney's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProKidney Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Debt-to-EBITDA | -0.06 | -0.03 | -0.02 | -0.04 |
ProKidney Quarterly Data | |||||||||||||
Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.02 | -0.02 | -0.02 | -0.02 | -0.06 |
For the Biotechnology subindustry, ProKidney's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ProKidney's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ProKidney's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
ProKidney's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.803 | + | 3.61) | / | -125.586 | |
= | -0.04 |
ProKidney's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.803 | + | 3.61) | / | -71.136 | |
= | -0.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.
ProKidney (NAS:PROK) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of ProKidney's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Chamath Palihapitiya | 10 percent owner | THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025 |
Sc Pipe Holdings Llc | 10 percent owner | 506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025 |
Sc Master Holdings, Llc | 10 percent owner | 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025 |
Bruce Culleton | officer: EVP, Clinical Development | 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103 |
Aaron Cowen | 10 percent owner | 540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Mary Weger | officer: Chief People Officer | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
William F Doyle | director | |
Tolerantia, Llc | 10 percent owner | 110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022 |
Jimenez Santos Jose Ignacio | director | C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103 |
Deepak Jain | officer: Chief Operating Officer | C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103 |
Darin J. Weber | officer: SVP of Regulatory Development | C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103 |
Libbie Parker Mckenzie | officer: Chief Medical Officer | C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103 |
James Coulston | officer: Chief Financial Officer | C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103 |
Jennifer A. Fox | director | C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036 |
Timothy Bertram | director, officer: Chief Executive Officer | C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403 |
From GuruFocus
By sperokesalga sperokesalga • 06-13-2023
By Marketwired • 09-05-2023
By GuruFocus Research • 11-14-2023
By sperokesalga sperokesalga • 03-03-2023
By GlobeNewswire GlobeNewswire • 11-11-2022
By Marketwired • 07-17-2023
By Marketwired • 07-18-2023
By Tiesvg Tiesvg • 12-22-2022
By Value_Insider Value_Insider • 11-03-2022
By Ds*** Ds*** • 08-31-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.